BLB Solicitors - The Leading Chronic Pain & CRPS Solicitors
BLB Solicitors - The Leading Chronic Pain & CRPS Solicitors
  • Home
  • About Us
    • Andrew Atkinson
    • Bruce Dyer
    • Clare Lowes
    • David Gazzard
    • Mark Tawn
    • Richard Lowes
  • Pain Conditions
    • CRPS Compensation
    • Fibromyalgia Solicitors
    • Myofascial Pain Syndrome Compensation Claim
    • Somatic Symptom Disorder Compensation Claim
    • Neuropathic Pain Compensation Claim
    • Functional Neurological Disorder Compensation
    • Chronic Fatigue Syndrome (ME) Compensation Claim
    • Chronic Pain Syndrome Compensation Claim
  • Unhappy With Your Solicitor?
  • Case Studies
    • Testimonials
  • Blog
  • Contact Us

Home » Memantine for CRPS: a new study

Complex Regional Pain Syndrome Nov 17th, 2021
White Pill Capsules

Memantine for CRPS: a new study

Visit our comprehensive Chronic Pain information hub.

Many studies have demonstrated the contribution of the central nervous system (CNS) to the development of neuropathic pain syndromes, including Complex Regional Pain Syndrome (CRPS). More specifically, modelling has demonstrated the involvement of the not-so-catchily-titled N-methyl-D-aspartate-receptors in the CNS. In turn, this has led researchers to investigate the effect of a suitable drug (antagonist) that can dampen down or block the reaction of these receptors.

Memantine

One such antagonist is Memantine, a drug more usually associated with the treatment of moderate to severe confusion related to Alzheimer’s disease. Memantine is not a cure, but it may improve a person’s memory and awareness, increasing their ability to function.

As long ago as 2007, a small-scale study examined the effect of treating six people diagnosed with CRPS in one upper limb with Memantine for eight weeks.

This study showed that six months after their treatment with Memantine, all participants demonstrated a significant decrease in their pain levels, coinciding with an improvement in motor symptoms and autonomic changes. Further, brain imaging studies of the same patients provided evidence of changes in an area of the brain called the somatosensory cortex. The affected side of the brain returned to a pattern comparable with the unaffected side following the treatment.

Australian Memantine study

Now, researchers in Australia are recruiting participants for a placebo-controlled trial of Memantine in conjunction with Graded Motor Imagery (GRI) for CRPS. The trial, which has been named MEMOIR, is described as follows:

“MEMOIR is an Australian government-funded clinical trial for people living with Complex Regional Pain Syndrome (CRPS). MEMOIR is testing two new interventions for people with CRPS – a medicine and newly developed rehabilitation program.”

This trial has the potential to become the most extensive study yet involving Memantine treatment for CRPS, although results are not expected before 2023.

Andrew Atkinson
Make an Enquiry

Contact Us

Contact Form

Left Column

Right Column

Centre

 
Sending

Recent Articles

  • Meet your chronic pain solicitor: Andrew Atkinson
  • CRPS on the rise but 62% of the UK have never heard of it
  • New fibromyalgia diagnostic guidelines
  • Could spider venom hold the key to treating chronic pain?
  • Study suggests Botox can prolong the benefit of a nerve block for CRPS

Share this Article

Newsletter Sign-up

* indicates required

Legal Glossary

Find Out More

You may also like...

  • Oct 4th, 2021
    CRPS Budapest Criteria amended
    Read Article
  • Jan 6th, 2022
    Study suggests Botox can prolong the benefit of a nerve block for CRPS
    Read Article
View All Related Articles

Get in Touch Today

Contact Form

Left Column

Right Column

Centre

 
Sending

1 Edgar Buildings,
George Street,
Bath, BA1 2DU

01225 462871 01225 445060
Authorised & Regulated by Solicitors Regulation Authority (No. 636644).
©2022 BLB Solicitors  |  Privacy & Terms